ImmunityBio Inc. (IBRX)
undefined
undefined%
At close: undefined
2.91
1.93%
After-hours Dec 13, 2024, 07:58 PM EST

Company Description

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases.

It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.

The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV.

It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

The company was founded in 2014 and is based in San Diego, California.

ImmunityBio Inc.
ImmunityBio Inc. logo
Country United States
IPO Date Jul 28, 2015
Industry Biotechnology
Sector Healthcare
Employees 672
CEO Richard Gerald Adcock

Contact Details

Address:
3530 John Hopkins Court
San Diego, California
United States
Website https://immunitybio.com

Stock Details

Ticker Symbol IBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326110
CUSIP Number 45256X103
ISIN Number US45256X1037
Employer ID 43-1979754
SIC Code 2836

Key Executives

Name Position
Richard Gerald Adcock President, Chief Executive Officer & Director
David C. Sachs Chief Financial Officer
Dr. Enrique Diloné Ph.D., RAC Chief Technology Officer
Dr. Leonard S. Sender M.D. Chief Operating Officer
Dr. Barry J. Simon M.D. Chief Corporate Affairs Officer & Director
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. Executive Chairman of the Board and Global Chief Scientific & Medical Officer
Dr. Sandeep K. Reddy M.D. Chief Medical Officer
Jason R. Liljestrom J.D. General Counsel & Corporate Secretary
Regan J. Lauer Chief Accounting Officer
Sarah Singleton Chief Communications Officer & Head of Patient Advocacy

Latest SEC Filings

Date Type Title
Dec 12, 2024 4 Filing
Dec 12, 2024 424B5 Filing
Dec 11, 2024 8-K Current Report
Dec 10, 2024 8-K Current Report
Dec 10, 2024 424B5 Filing
Nov 19, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Aug 12, 2024 10-Q Quarterly Report
Jul 18, 2024 8-K Current Report
Jun 20, 2024 S-8 Filing